 |
David ReismanAssociate Professor of Biological Sciences |
Dept. of Biological Sciences
| |
David ReismanAssociate Professor of Biological Sciences |
It is now well established that the wild-type p53 gene encodes a protein that has properties of a negative growth regulator that induces exit from the cell cycle upon damage to DNA. In many transformed cells and primary tumors, mutant p53 proteins that have lost many of p53's growth suppressing functions are detected at elevated levels. Some mutant p53 alleles may be oncogenic and contribute to the transformed phenotype. We have demonstrated that elevated transcription of the p53 gene can contributed to elevated p53 expression in tumor cells. The major goals of our research are to define the role that mutant p53 plays in transformation and to determine the mechanisms that lead to de-regulated expression of the p53 gene.
Boggs, K. and Reisman, D. (2005) Increased transcription of p53 prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter. In press, Oncogene
Reisman, D., Wallace, J., and Lu, G. (2004) Loss of heterozygosity and p53 expression in Pterygium. Cancer Letters, 206, 77-83.
Durland-Busbice, S. and Reisman, D. (2002) The lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene. Leukemia, 16 2165 - 2167.
Reisman, D., Eaton, E., McMillin, D., Doudican, N. and Boggs, K. (2001) Cloning and characterization of murine upstream sequences reveals additional positive regulatory elements. Gene, 274, 129-137.
Raman, V., Martensen, S.A., Reisman, D., Evron, E., Odenwald, W.F., Jaffee, E., Marks, J. and Sukumar, S. (2000). Control of p53 transcription by HOXA5 may play a role in breast cancer. Nature, 405, 974-978.
Reisman, D., Durland-Busbice, S., and Loging, W. (2000) Regulation of gene expression by tumor derived p53 mutants. Recent Research Developments in Cancer. 1, 181-200.
Loging, W.T. and Reisman, D. (1999) Inhibition of the Putative Tumor Suppressor Gene TIMP-3 by Tumor-derived p53 Mutants and Wild Type p53. Oncogene, 18, 7608-7613.
Loging, W.T. and Reisman, D. (1999) Elevated Expression of Ribosomal Protein Genes RPP-1, L37, and S2 in the Presence of Mutant p53. Cancer Epidemiology, Biomarkers, and Prevention, 8, 1011-6.
Reisman, D. and Loging, W.T. (1998) Transcriptional Regulation of the p53 Tumor Suppressor Gene Seminars in Cancer Biology 8, 317-324.
Reisman, D., Balint, E., Loging, W.T., Rotter, V., and Almon, E. (1996) A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during the differentiation of myeloid leukemia cells. Genomics 39, 1648-1653.
Roy, B. and Reisman, D. (1996) Positive and negative regulatory elements contribute to expression of the p53 tumor suppressor gene Oncogene. 13, 2359-2366.
Balint, E. and Reisman, D. (1996) Increased rate of transcription contributes to elevated expression of the mutant p53 gene in Burkitt's lymphoma cells. Cancer Research. 56, 1648-1653.
Uttenbogaard, M.N., Giebler, H.A., Reisman, D., and Nyborg, J.K. (1995) Transcriptional repression of p53 by the human T-cell leukemia virus type I tax protein. J. Biol. Chem. 270, 28503-28506.
Roy, B., Beamon, J., Balint, E. and Reisman, D. (1994) Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol. and Cell. Biol. 14, 7805-7815.